M
25
5
ABBV
39
8
HAL
60
2
FDX
40
4
ILMN
37
5
CRM
65
6
LRCX
45
6
QRVO
8
4
UNP
45
6
BBY
36
-4
SHW
65
7
CMG
67
3
WDC
43
2
EXPD
45
8
CMI
64
5
BSX
70
2
ALLE
44
7
SYY
49
2
ZTS
49
2
EXPE
91
3
M
25
5
ABBV
39
8
HAL
60
2
FDX
40
4
ILMN
37
5
CRM
65
6
LRCX
45
6
QRVO
8
4
UNP
45
6
BBY
36
-4
SHW
65
7
CMG
67
3
WDC
43
2
EXPD
45
8
CMI
64
5
BSX
70
2
ALLE
44
7
SYY
49
2
ZTS
49
2
EXPE
91
3
Financhill
Back

Zevra Therapeutics 10K Form

Buy
67

ZVRA
Zevra Therapeutics

Last Price:
9.37
Seasonality Move:
6.65%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ZVRA News And Ratings

See the #1 stock for the next 7 days that we like better than ZVRA

ZVRA Financial Statistics

Sales & Book Value

Annual Sales: $27.46M
Cash Flow: $-18.14M
Price / Cash Flow: 0
Annual Sales: $1.31
Price / Book: 6.98

Profitability

EPS (TTM): -2.11000
Net Income (TTM): $-89.66M
Gross Margin: $24.52M
Return on Equity: -159.89%
Return on Assets: -56.14%

Zevra Therapeutics Earnings Forecast

Key Zevra Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for ZVRA is 89.28%.
  • The Selling, General & Administrative Expenses for ZVRA have been equal to 124.96% of Gross Profit Margin.
  • The Research & Development expenses have been 144.95% of Revenue.
  • The Interest Expense is -3.26% of Operating Income.
  • The Net Earning history of ZVRA is -167.69% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Zevra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ZVRA
Website: zevra.com

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 2.88
Quick Ratio: 2.82

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ZVRA Technical Analysis vs Fundamental Analysis

Buy
67
Zevra Therapeutics (ZVRA) is a Buy

Is Zevra Therapeutics a Buy or a Sell?